PLCB1 and prostate adenocarcinoma: It is also an essential biomarker and promising immunotherapeutic target in hematologic malignancies.[22,23] PLCB1 involved tumorigenesis in various cancer types, such as hepatocellular carcinoma, cholangiocarcinoma, and non-small cell lung carcinoma.[24–26] This finding suggested that it could participate in the tumor development and progression in the PRAD.